公开(公告)号：US20230355753A1

公开(公告)日：2023-11-09

申请号：US18025206

申请日：2021-09-10

Applicant: GENMAB A/S

Inventor： Brian ELLIOTT ,  Tahamtan AHMADI

IPC: A61K39/395 ,  A61P35/00 ,  A61K31/573 ,  A61K31/7068 ,  A61K31/282

CPC classification number: A61K39/3955 ,  A61P35/00 ,  A61K31/573 ,  A61K31/7068 ,  A61K31/282 ,  A61K2039/545

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).

公开(公告)号：US20220144964A1

公开(公告)日：2022-05-12

申请号：US17559938

申请日：2021-12-22

Applicant: GENMAB A/S

Inventor： Brian ELLIOTT ,  Tahamtan AHMADI ,  Christopher W. L. CHIU ,  Esther C. W. BREIJ ,  Ida HIEMSTRA ,  Maria N. JURE-KUNKEL

IPC: C07K16/28 ,  A61K31/454

Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.

公开(公告)号：US20210371538A1

公开(公告)日：2021-12-02

申请号：US17314946

申请日：2021-05-07

Applicant: GENMAB A/S

Inventor： Tahamtan AHMADI ,  Manish GUPTA ,  Tommy LI ,  Roberto OLIVERI ,  Dena DEMARCO ,  Ida HIEMSTRA ,  Christopher CHIU ,  Brian ELLIOTT ,  Ada AZARYAN

IPC: C07K16/28 ,  A61K31/573 ,  A61K45/06 ,  A61K39/395 ,  A61P35/00

Abstract: The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).